Sphenoid plasmacytoma as initial presentation of multiple myeloma—case report

Abstract

Plasmacytoma is a rare plasma cell neoplasm. Whether solitary or associated with multiple myeloma (MM), it rarely involves the skull base, particularly the sphenoid bone. We present a unique case of sphenoid bone plasmacytoma secondary to MM, highlighting diagnostic and therapeutic challenges. A 56-year-old female presented with headaches, vomiting, epistaxis, and cranial nerve deficits. Cerebral imaging revealed a 65-mm tumor infiltrating the sphenoid bone and adjacent structures. Subtotal resection was performed using an endoscopic nasal approach. Histopathology revealed plasmacytoma, and diagnostic workup confirmed MM. By the end of biological exploration, relapse of the sphenoid plasmacytoma was observed, and the patient was successfully treated with radiotherapy, immunochemotherapy, and autologous stem cell transplantation. After 18-month follow-up, sustained complete remission was confirmed. Although rare, the diagnosis of plasmacytoma should be considered in cases of skull base tumors. This localization is highly predictive of MM, warranting comprehensive investigations to initiate prompt and adequate management.

plasmacytoma, multiple myeloma, sphenoid bone, skull base neoplasms, case reports

Introduction

Plasmacytoma is a rare neoplasm characterized by the localized proliferation of a single clone of plasma cells. It may be solitary or associated with multiple myeloma (MM), eventually being its initial presentation. Whether originating from bone or soft tissue, intracranial involvement of plasmacytoma is an unusual phenomenon, particularly at the skull base [1].

Clinical and radiological differentiation from other regional tumors is often challenging, potentially leading to misdiagnosis. Given the notable differences in therapeutic strategies and outcomes, timely recognition of plasmacytoma is of utmost importance.

Here, we present an illustrative case of a patient with multiple cranial nerve deficits and signs of increased intracranial pressure revealing a skull base sphenoid bone plasmacytoma (BP), secondary to MM. This case highlights the complexity involved in diagnosing and managing such patients.

Case report

A 56-year-old female patient, presented with a 2-week history of moderate headaches, intermittent vomiting, epistaxis, and blurred vision. Physical examination revealed decreased visual acuity (5/10 left eye, 7/10 right eye) and bilateral papilledema, with left peripheral facial palsy and trigeminal hypoesthesia.

Cerebral computed tomography (CT) revealed a 65-mm hyperdense tumor invading the sphenoid bone and sinus, and eroding the adjacent skull base and clivus. On magnetic resonance imaging (MRI), the tumor appeared isointense on T1 and hypointense on T2-weighted images, showing mild heterogeneous enhancement after gadolinium injection. Local compression and extension to the left cavernous sinus, internal carotid artery, and optic chiasm were observed (Fig. 1).

Figure 1

Cerebral MRI (axial views) showing a 65-mm lesion centered on the sphenoid bone (red arrow) with extension to the internal carotid artery (blue arrow), demonstrating iso-intensity with mild heterogeneous enhancement on T1-weighted (a, b) and hypo-intensity on T2-weighted (c).

Open in new tab Download slide

The patient underwent an endoscopic endonasal approach for debulking and cranial nerve decompression, which revealed a relatively soft, multilayered, reddish tumor, with moderate bleeding. Per-operative frozen section analysis was inconclusive. Resection was conducted to near complete with satisfactory decompression of nervous structures, as confirmed by postoperative cerebral CT, leading to significant improvement in neurological symptoms.

Histopathological examination revealed monoclonal proliferation of dystrophic plasma cells, thereby identifying plasmacytoma (Fig. 2). Serum protein immunoelectrophoresis showed a narrow peak in gammaglobulins (15 g/l) with a monoclonal IgG kappa band. Serum free light chain (sFLC) kappa was elevated at 299 mg/L, with lambda at 78 mg/l, and a K/L ratio of 3.8. Bone marrow aspiration did not reveal abnormal plasma cells or high-risk cytogenetic abnormalities. Bence–Jones proteinuria was negative. Diffuse osteolytic lesions were visualized in the spine. There was no associated anemia, hypercalcemia, or renal failure. Albumin, beta-2-microglobulin, and lactate dehydrogenase levels were normal. Subsequently, the patient was diagnosed with stage I IgG kappa MM.

Figure 2

Histology section showing diffuse dystrophic plasma cells predominantly mature (left), with positive CD138 staining on immunohistochemistry (right).

Open in new tab Download slide

By the end of biological exploration, the patient reported a recurrence of headaches and blurred vision, 2 months after surgical decompression. Cerebral MRI revealed a relapse of the sphenoid plasmacytoma, measuring 70 mm (Fig. 3). Given the pathological diagnostic result, surgical re-intervention was not decided. Instead, the patient was treated with external beam radiotherapy (RTX) focused on the sphenoid bone (30 Gy), followed by immunochemotherapy with zoledronic acid. After 6 months, complete response was noted with the resolution of symptoms, disappearance of the monoclonal band, normalization of sFLC, and persistence of lytic sequelae on cerebral MRI (Fig. 4). Autologous stem cell transplantation (ASCT) was successfully performed, and the patient was put under treatment maintenance. After 18 months of follow-up, clinical, biological, and radiological evaluation confirmed sustained complete remission.

Figure 3

Cerebral MRI (axial views) showing a relapse of the sphenoid BP measuring 70 mm (a, b: T1 weighted post-gadolinium; c: T2 weighted).

Open in new tab Download slide

Figure 4

Control cerebral MRI (axial views) showing the disappearance of the sphenoid BP after treatment with RTX and immunochemotherapy. (a: T1-weighted; b: T2-weighted).

Open in new tab Download slide

Discussion

We report the case of a 56-year-old female patient who presented with headaches, intermittent vomiting, epistaxis, and multiple cranial nerve deficits attributed to a sphenoid bone mass. Surgical resection was performed, and histological examination identified a plasmacytoma secondary to IgG kappa MM. Following relapse, the initiation of RTX, immunochemotherapy, and ASCT enabled sustained clinical remission.

Plasma neoplasms are a group of hematological disorders defined by the clonal proliferation of plasma cells [2]. Plasmacytoma, the localized form (<4%), originates from osseous/intramedullary sites, called “BP,” or from non-osseous/extramedullary sites, called “extramedullary plasmacytoma” (EMP) [3]. BP is more frequent (70%), mainly involving the spine (30%–40%) and long bones (20%–40%) [4, 5]. However, intracranial involvement is uncommon, especially at the skull base. Only 14 cases of sphenoid plasmacytoma were reported, two associated with MM (Table 1) [1].

Table 1

Open in new tab

Summary of sphenoid plasmacytoma cases from the literature.

Case n°	Authors (year)	Sex	Age (years)	Symptoms	Primary site	PCN	Treatment	Evolution (months)
1	Losa et al. [18] (1992)	F	50	Diplopia	Sphenoid sinus	SP	Resection + RTX	LC
2	Marais et al. [19] (1992)	M	64	Headaches, diplopia	Sphenoid sinus	SP	RTX	LC (18)
3	Bindal et al. [20] (1995)	F	51	Diplopia	Sphenoid +clivus	SP	Resection + RTX	LC (96)
4	Miller et al. [21] (1998)	M	47	Headaches	Sphenoid sinus	SP	RTX	LC (62)
5	Mandagere et al. [22] (1998)	F	53	Headaches, blurry vision	Sphenoid	SP	RTX	LC (84)
6	Wein et al. [23] (2002)	M	48	Headaches, epistaxis	Sphenoid sinus +clivus	MM	RTX + CTX	ER
7	Akhaddar et al. [24] (2008)	M	83	Headaches, diplopia	Sphenoid	MM	RTX + CTX	ND
8	Lakhdar et al. [25] (2008)	F	62	Headaches, diplopia, anosmia	Sphenoid	SP	RTX	LC (12)
9	Park et al. [26] (2009)	M	32	Diplopia	Sphenoid	SP	Resection + RTX	LC (8)
10	Siyag et al. [27] (2018)	M	41	Headaches, diplopia, strabismus	Sphenoid +clivus	SP	RTX	LC (3)
11	Loong et al. [28] (2019)	F	43	Headaches, diplopia	Sphenoid	SP	RTX	ND
12	Sharifi et al. [29] (2022)	F	62	Headaches, ptosis, visual loss	Sphenoid	SP	Resection + RTX	LC (6)
13	Ampil et al. [30] (2022)	M	63	Headaches, diplopia	Sphenoid sinus	SP	Resection + RTX + CTX	LC (3)
14	Mansouri et al. [31] (2023)	F	51	Headaches, diplopia, visual loss, epistaxis	Sphenoid +clivus	SP	RTX	LC (12)
Our case		F	56	Headaches, vomiting, blurry vision, epistaxis	Sphenoid + clivus	MM	Resection + RTX + CTX + ASCT	CR (18)

Case n°	Authors (year)	Sex	Age (years)	Symptoms	Primary site	PCN	Treatment	Evolution (months)
1	Losa et al. [18] (1992)	F	50	Diplopia	Sphenoid sinus	SP	Resection + RTX	LC
2	Marais et al. [19] (1992)	M	64	Headaches, diplopia	Sphenoid sinus	SP	RTX	LC (18)
3	Bindal et al. [20] (1995)	F	51	Diplopia	Sphenoid +clivus	SP	Resection + RTX	LC (96)
4	Miller et al. [21] (1998)	M	47	Headaches	Sphenoid sinus	SP	RTX	LC (62)
5	Mandagere et al. [22] (1998)	F	53	Headaches, blurry vision	Sphenoid	SP	RTX	LC (84)
6	Wein et al. [23] (2002)	M	48	Headaches, epistaxis	Sphenoid sinus +clivus	MM	RTX + CTX	ER
7	Akhaddar et al. [24] (2008)	M	83	Headaches, diplopia	Sphenoid	MM	RTX + CTX	ND
8	Lakhdar et al. [25] (2008)	F	62	Headaches, diplopia, anosmia	Sphenoid	SP	RTX	LC (12)
9	Park et al. [26] (2009)	M	32	Diplopia	Sphenoid	SP	Resection + RTX	LC (8)
10	Siyag et al. [27] (2018)	M	41	Headaches, diplopia, strabismus	Sphenoid +clivus	SP	RTX	LC (3)
11	Loong et al. [28] (2019)	F	43	Headaches, diplopia	Sphenoid	SP	RTX	ND
12	Sharifi et al. [29] (2022)	F	62	Headaches, ptosis, visual loss	Sphenoid	SP	Resection + RTX	LC (6)
13	Ampil et al. [30] (2022)	M	63	Headaches, diplopia	Sphenoid sinus	SP	Resection + RTX + CTX	LC (3)
14	Mansouri et al. [31] (2023)	F	51	Headaches, diplopia, visual loss, epistaxis	Sphenoid +clivus	SP	RTX	LC (12)
Our case		F	56	Headaches, vomiting, blurry vision, epistaxis	Sphenoid + clivus	MM	Resection + RTX + CTX + ASCT	CR (18)

PCN: plasma cell neoplasm; M: male; F: female; MM: multiple myeloma; SP: solitary plasmacytoma; RTX: radiotherapy; CTX: chemotherapy; CR: complete remission; LC: local control; ER: early response; ND: non-documented.

Table 1

Open in new tab

Summary of sphenoid plasmacytoma cases from the literature.

Case n°	Authors (year)	Sex	Age (years)	Symptoms	Primary site	PCN	Treatment	Evolution (months)
1	Losa et al. [18] (1992)	F	50	Diplopia	Sphenoid sinus	SP	Resection + RTX	LC
2	Marais et al. [19] (1992)	M	64	Headaches, diplopia	Sphenoid sinus	SP	RTX	LC (18)
3	Bindal et al. [20] (1995)	F	51	Diplopia	Sphenoid +clivus	SP	Resection + RTX	LC (96)
4	Miller et al. [21] (1998)	M	47	Headaches	Sphenoid sinus	SP	RTX	LC (62)
5	Mandagere et al. [22] (1998)	F	53	Headaches, blurry vision	Sphenoid	SP	RTX	LC (84)
6	Wein et al. [23] (2002)	M	48	Headaches, epistaxis	Sphenoid sinus +clivus	MM	RTX + CTX	ER
7	Akhaddar et al. [24] (2008)	M	83	Headaches, diplopia	Sphenoid	MM	RTX + CTX	ND
8	Lakhdar et al. [25] (2008)	F	62	Headaches, diplopia, anosmia	Sphenoid	SP	RTX	LC (12)
9	Park et al. [26] (2009)	M	32	Diplopia	Sphenoid	SP	Resection + RTX	LC (8)
10	Siyag et al. [27] (2018)	M	41	Headaches, diplopia, strabismus	Sphenoid +clivus	SP	RTX	LC (3)
11	Loong et al. [28] (2019)	F	43	Headaches, diplopia	Sphenoid	SP	RTX	ND
12	Sharifi et al. [29] (2022)	F	62	Headaches, ptosis, visual loss	Sphenoid	SP	Resection + RTX	LC (6)
13	Ampil et al. [30] (2022)	M	63	Headaches, diplopia	Sphenoid sinus	SP	Resection + RTX + CTX	LC (3)
14	Mansouri et al. [31] (2023)	F	51	Headaches, diplopia, visual loss, epistaxis	Sphenoid +clivus	SP	RTX	LC (12)
Our case		F	56	Headaches, vomiting, blurry vision, epistaxis	Sphenoid + clivus	MM	Resection + RTX + CTX + ASCT	CR (18)

Case n°	Authors (year)	Sex	Age (years)	Symptoms	Primary site	PCN	Treatment	Evolution (months)
1	Losa et al. [18] (1992)	F	50	Diplopia	Sphenoid sinus	SP	Resection + RTX	LC
2	Marais et al. [19] (1992)	M	64	Headaches, diplopia	Sphenoid sinus	SP	RTX	LC (18)
3	Bindal et al. [20] (1995)	F	51	Diplopia	Sphenoid +clivus	SP	Resection + RTX	LC (96)
4	Miller et al. [21] (1998)	M	47	Headaches	Sphenoid sinus	SP	RTX	LC (62)
5	Mandagere et al. [22] (1998)	F	53	Headaches, blurry vision	Sphenoid	SP	RTX	LC (84)
6	Wein et al. [23] (2002)	M	48	Headaches, epistaxis	Sphenoid sinus +clivus	MM	RTX + CTX	ER
7	Akhaddar et al. [24] (2008)	M	83	Headaches, diplopia	Sphenoid	MM	RTX + CTX	ND
8	Lakhdar et al. [25] (2008)	F	62	Headaches, diplopia, anosmia	Sphenoid	SP	RTX	LC (12)
9	Park et al. [26] (2009)	M	32	Diplopia	Sphenoid	SP	Resection + RTX	LC (8)
10	Siyag et al. [27] (2018)	M	41	Headaches, diplopia, strabismus	Sphenoid +clivus	SP	RTX	LC (3)
11	Loong et al. [28] (2019)	F	43	Headaches, diplopia	Sphenoid	SP	RTX	ND
12	Sharifi et al. [29] (2022)	F	62	Headaches, ptosis, visual loss	Sphenoid	SP	Resection + RTX	LC (6)
13	Ampil et al. [30] (2022)	M	63	Headaches, diplopia	Sphenoid sinus	SP	Resection + RTX + CTX	LC (3)
14	Mansouri et al. [31] (2023)	F	51	Headaches, diplopia, visual loss, epistaxis	Sphenoid +clivus	SP	RTX	LC (12)
Our case		F	56	Headaches, vomiting, blurry vision, epistaxis	Sphenoid + clivus	MM	Resection + RTX + CTX + ASCT	CR (18)

BP typically manifests with variable mass effect, pain, and infiltrative behavior [6]. When located at the skull, it may grow asymptomatic, only manifesting when reaching large sizes and infiltrating neural elements, as was observed in our case [7]. The patient presented multiple cranial nerve deficits mainly attributed to a direct compressive effect. These findings are usually present in tumors involving the sphenoid bone, petrous bone, and cavernous sinus [5].

Radiologically, BP appears as a well-circumscribed mass on CT scan, often associated with lytic lesions and infiltration of adjacent structures. On MRI, discrete heterogeneity is generally observed, with iso to hyperintensity on T1 and iso to hypointensity on T2-weighted images, and mild to vivid homogeneous contrast enhancement [8, 9]. Yet, these radiological findings are not specific to plasmacytoma and may be difficult to differentiate from other regional tumors (chordoma, chondroma, carcinomas, etc.) [10].

The diagnosis of plasmacytoma is established on immunohistological examination showing diffuse infiltration by monoclonal dystrophic plasma cells. Serum and urine immunoelectrophoresis must be performed to detect monoclonal protein [11]. To differentiate solitary plasmacytoma (SP; Table 2) from MM, bone marrow involvement and organ damage evidence that can be attributed to MM, including additional sites of bone lesions, must be investigated (Table 3) [12, 13]. If MM is confirmed, risk stratification is needed to further guide management (Table 4).

Table 2

Open in new tab

International Myeloma Working Group diagnostic criteria for SP [12].

All four criteria must be met
– Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells
– Normal bone marrow with no evidence of clonal plasma cells
– Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)
– Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lympho-plasma cell proliferative disorder

All four criteria must be met
– Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells
– Normal bone marrow with no evidence of clonal plasma cells
– Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)
– Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lympho-plasma cell proliferative disorder

Table 2

Open in new tab

International Myeloma Working Group diagnostic criteria for SP [12].

All four criteria must be met
– Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells
– Normal bone marrow with no evidence of clonal plasma cells
– Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)
– Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lympho-plasma cell proliferative disorder

All four criteria must be met
– Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells
– Normal bone marrow with no evidence of clonal plasma cells
– Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)
– Absence of end-organ damage such as hypercalcemia, renal insufficiency, anemia, or bone lesions (CRAB) that can be attributed to a lympho-plasma cell proliferative disorder

Table 3

Open in new tab

International Myeloma Working Group diagnostic criteria for MM [12].

Both criteria must be met:
– Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or EMP
– Any one or more of the following myeloma-defining events: ➢ Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder: Hypercalcemia: Ca > 0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or Ca > 2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: Hb >2 g/dL below the lower limit of normal, or a Hb < 10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, PET-CT ➢ Clonal bone marrow plasma cell percentage ≥ 60% ➢ Involved/uninvolved sFLC ratio ≥ 100 (involved FLC level must be ≥100 mg/L) ➢ >1 focal lesion on MRI studies (at least 5 mm in size)

Both criteria must be met:

– Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or EMP

– Any one or more of the following myeloma-defining events:

➢ Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder:
- Hypercalcemia: Ca > 0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or Ca > 2.75 mmol/L (>11 mg/dL)
- Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 μmol/L (>2 mg/dL)
- Anemia: Hb >2 g/dL below the lower limit of normal, or a Hb < 10 g/dL
- Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, PET-CT
➢ Clonal bone marrow plasma cell percentage ≥ 60%
➢ Involved/uninvolved sFLC ratio ≥ 100 (involved FLC level must be ≥100 mg/L)
➢ >1 focal lesion on MRI studies (at least 5 mm in size)

Abbreviations: Ca: serum calcium; Hb: hemoglobin; PET-CT: positron emission tomography-CT; FLC: free light chains; sFLC: serum free light chains.

Table 3

Open in new tab

International Myeloma Working Group diagnostic criteria for MM [12].

Both criteria must be met:
– Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or EMP
– Any one or more of the following myeloma-defining events: ➢ Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder: Hypercalcemia: Ca > 0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or Ca > 2.75 mmol/L (>11 mg/dL) Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 μmol/L (>2 mg/dL) Anemia: Hb >2 g/dL below the lower limit of normal, or a Hb < 10 g/dL Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, PET-CT ➢ Clonal bone marrow plasma cell percentage ≥ 60% ➢ Involved/uninvolved sFLC ratio ≥ 100 (involved FLC level must be ≥100 mg/L) ➢ >1 focal lesion on MRI studies (at least 5 mm in size)

Both criteria must be met:

– Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or EMP

– Any one or more of the following myeloma-defining events:

➢ Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder:
- Hypercalcemia: Ca > 0.25 mmol/L (>1 mg/dL) higher than the upper limit of normal or Ca > 2.75 mmol/L (>11 mg/dL)
- Renal insufficiency: creatinine clearance <40 mL per minute or serum creatinine >177 μmol/L (>2 mg/dL)
- Anemia: Hb >2 g/dL below the lower limit of normal, or a Hb < 10 g/dL
- Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, PET-CT
➢ Clonal bone marrow plasma cell percentage ≥ 60%
➢ Involved/uninvolved sFLC ratio ≥ 100 (involved FLC level must be ≥100 mg/L)
➢ >1 focal lesion on MRI studies (at least 5 mm in size)

Abbreviations: Ca: serum calcium; Hb: hemoglobin; PET-CT: positron emission tomography-CT; FLC: free light chains; sFLC: serum free light chains.

Table 4

Open in new tab

Revised International Staging System (R-ISS) for MM [32].

Stages	Criteria
Stage I	All the following: Serum albumin 3.5 mg/dl Serum beta-2-microglobulin <3.5 mg/dl No high-risk cytogenetics Normal serum lactate dehydrogenase level
Stage II	Not fitting Stage I or III
Stage III	Both of the following: Serum beta-2-microglobulin >5.5 mg/l High risk cytogenetics [t(4;14), t(14;16), or del(17p)] OR elevated serum lactate dehydrogenase level

Stages	Criteria
Stage I	All the following: Serum albumin 3.5 mg/dl Serum beta-2-microglobulin <3.5 mg/dl No high-risk cytogenetics Normal serum lactate dehydrogenase level
Stage II	Not fitting Stage I or III
Stage III	Both of the following: Serum beta-2-microglobulin >5.5 mg/l High risk cytogenetics [t(4;14), t(14;16), or del(17p)] OR elevated serum lactate dehydrogenase level

Abbreviations: t: translocation; del: deletion.

Table 4

Open in new tab

Revised International Staging System (R-ISS) for MM [32].

Stages	Criteria
Stage I	All the following: Serum albumin 3.5 mg/dl Serum beta-2-microglobulin <3.5 mg/dl No high-risk cytogenetics Normal serum lactate dehydrogenase level
Stage II	Not fitting Stage I or III
Stage III	Both of the following: Serum beta-2-microglobulin >5.5 mg/l High risk cytogenetics [t(4;14), t(14;16), or del(17p)] OR elevated serum lactate dehydrogenase level

Stages	Criteria
Stage I	All the following: Serum albumin 3.5 mg/dl Serum beta-2-microglobulin <3.5 mg/dl No high-risk cytogenetics Normal serum lactate dehydrogenase level
Stage II	Not fitting Stage I or III
Stage III	Both of the following: Serum beta-2-microglobulin >5.5 mg/l High risk cytogenetics [t(4;14), t(14;16), or del(17p)] OR elevated serum lactate dehydrogenase level

Abbreviations: t: translocation; del: deletion.

Approximately 50% of plasmacytomas progress to MM, with a higher risk for BP (60%–70%) than EMP (10%–20%) [6]. Moreover, its localization at the skull base is highly predictive of MM. However, our case is only the third reported of sphenoid plasmacytoma related to MM. Other risk factors correlated with this progression include age over 40 years, lesion > 5 cm, high monoclonal protein level, and persistence of residual disease after treatment [14, 15].

Because plasmacytomas are highly radiosensitive, RTX represents the mainstay of management, with or without surgery [16, 17]. Lesions at the skull base may be treated by subtotal resection followed by irradiation or by irradiation alone. Immunochemotherapy, with ASCT for eligible patients, is indicated in refractory plasmacytomas and MM [12, 13].

Although the prognosis of SP is favorable, long-term follow-up is required because of the risk of progression. The survival of patients with MM ranges from several months to more than 10 years, with a 3-year median life expectancy for skull base plasmacytomas. However, patient outcomes have drastically improved in recent decades with novel immunochemotherapy and ASCT [1, 12, 13].

Conclusion

Although rare, sphenoid BP should be considered in the differential diagnosis of skull base tumors. This localization is highly predictive of MM, which needs to be thoroughly investigated. Our patient achieved sustained complete remission following RTX, immunochemotherapy, and ASCT.

Conflict of interest statement

None declared.

Funding

None declared.

References

Liu

Shen

Liu

Case reports: central nervous system involvement in patients with newly diagnosed multiple myeloma

Front Neurol

2023

;

1072490

. https://doi.org/10.3389/fneur.2023.1072490.

Pollard

Young

GAR

Neurology and the bone marrow

J Neurol Neurosurg Psychiatry

1997

;

706

–

. https://doi.org/10.1136/jnnp.63.6.706.

Bolek

Marcus

Mendenhall

Solitary plasmacytoma of bone and soft tissue

Int J Radiat Oncol Biol Phys

1996

;

329

–

. https://doi.org/10.1016/S0360-3016(96)00334-3.

Megdiche Bazarbacha

Jeribi

Zidi

, et al.

Plasmocytome de la base du crâne révélant un myélome multiple

J Radiol

2005

;

1810

–

. https://doi.org/10.1016/S0221-0363(05)81528-8.

Pancholi

Raniga

Vohra

, et al.

“Imaging features of extramedullary plasmacytoma of skull base with multiple myeloma” - a rare case

Indian J Radiol Imaging

2006

;

–

. https://doi.org/10.4103/0971-3026.29040.

Google Scholar

OpenURL Placeholder Text

WorldCat

Cerase

Tarantino

Gozzetti

, et al.

Intracranial involvement in plasmacytomas and multiple myeloma: a pictorial essay

Neuroradiology

2008

;

665

–

. https://doi.org/10.1007/s00234-008-0390-x.

Ustuner

Basaran

Kiris

, et al.

Skull base plasmacytoma in a patient with light chain myeloma

Skull Base

2003

;

167

–

. https://doi.org/10.1055/s-2003-43327.

Agarwal

Neuroimaging of plasmacytoma

Neuroradiol J

2014

;

431

–

. https://doi.org/10.15274/NRJ-2014-10078.

Grammatico

Scalzulli

Petrucci

Solitary plasmacytoma

Mediterr J Hematol Infect Dis

2017

;

e2017052

. https://doi.org/10.4084/mjhid.2017.052.

10.

Higurashi

Yagishita

Fujitsu

, et al.

Plasma cell myeloma of the skull base: report of two cases

Brain Tumor Pathol

2004

;

135

–

. https://doi.org/10.1007/BF02482189.

11.

Dimopoulos

Moulopoulos

Maniatis

, et al.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

Blood

2000

;

2037

–

. https://doi.org/10.1182/blood.V96.6.2037.

12.

Rajkumar

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

Am J Hematol

2022

;

1086

–

107

. https://doi.org/10.1002/ajh.26590.

13.

Cowan

Green

Kwok

, et al.

Diagnosis and management of multiple myeloma: a review

JAMA

2022

;

327

464

–

. https://doi.org/10.1001/jama.2022.0003.

14.

Seetahal-Maraj

Knight

Ramnarine

Proptosis secondary to a solitary plasmacytoma of the sphenoid bone: a case report on a rare skull base tumor

Egypt J Neurosurg

2022

;

. https://doi.org/10.1186/s41984-022-00144-2.

Google Scholar

Crossref

WorldCat

15.

de Waal

EGM

Leene

Veeger

, et al.

Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands

Br J Haematol

2016

;

175

661

–

. https://doi.org/10.1111/bjh.14291.

16.

Tsang

Campbell

Goda

, et al.

Radiation therapy for solitary plasmacytoma and multiple myeloma: guidelines from the international lymphoma radiation oncology group

Int J Radiat Oncol Biol Phys

2018

;

101

794

–

808

. https://doi.org/10.1016/j.ijrobp.2018.05.009.

17.

Suh

Y-G

Suh

C-O

Kim

, et al.

Radiotherapy for solitary plasmacytoma of bone and soft tissue

Ann Hematol

2012

;

1785

–

. https://doi.org/10.1007/s00277-012-1510-6.

18.

Losa

Terreni

Tresoldi

, et al.

Solitary plasmacytoma of the sphenoid sinus involving the pituitary fossa: a case report and review of the literature

Surg Neurol

1992

;

388

–

. https://doi.org/10.1016/0090-3019(92)90010-K.

19.

Marais

Brookes

Lee

Solitary plasmacytoma of the skull base

Ann Otol Rhinol Laryngol

1992

;

101

665

–

. https://doi.org/10.1177/000348949210100807.

Google Scholar

PubMed

OpenURL Placeholder Text

WorldCat

20.

Bindal

van

Loveren

, et al.

Management of intracranial plasmacytoma

J Neurosurg

1995

;

218

–

. https://doi.org/10.3171/jns.1995.83.2.0218.

21.

Miller

Lavertu

Wanamaker

, et al.

Plasmacytomas of the head and neck

Otolaryngol Head Neck Surg

1998

;

119

614

–

. https://doi.org/10.1016/S0194-5998(98)70021-X.

22.

Mandagere

Schimke

Kyner

, et al.

An unusual sellar mass--solitary plasmacytoma

Endocr Pract

1998

;

382

–

. https://doi.org/10.4158/EP.4.6.382.

23.

Wein

Popat

Doerr

, et al.

Plasma cell tumors of the skull base: four case reports and literature review

Skull Base

2002

;

077

–

. https://doi.org/10.1055/s-2002-31570-1.

Google Scholar

Crossref

WorldCat

24.

Akhaddar

Belhachmi

Albouzidi

, et al.

Multiple myeloma revealing by sphenoid involvement. Case Report

AJNS

2008

;

126

Google Scholar

OpenURL Placeholder Text

WorldCat

25.

Lakhdar

Arkha

Derraz

, et al.

Solitary intrasellar plasmocytoma revealed by a diplopia: a case report

Neurochirurgie

2012

;

–

. https://doi.org/10.1016/j.neuchi.2011.09.002.

26.

Park

Kim

Lee

, et al.

Endoscopic endonasal transsphenoidal resection of solitary extramedullary plasmacytoma in the sphenoid sinus with destruction of skull base

J Korean Neurosurg Soc

2009

;

156

–

. https://doi.org/10.3340/jkns.2009.46.2.156.

27.

Siyag

Soni

Gupta

, et al.

Plasmacytoma of the skull-base: a rare tumor

Cureus

:e2073.

OpenURL Placeholder Text

WorldCat

28.

Loong

Afandi

Lum

, et al.

Solitary extramedullary plasmacytoma of the sphenoid sinus: a case report

Indian J Otolaryngol Head Neck Surg

2019

;

1692

–

. https://doi.org/10.1007/s12070-015-0945-1.

29.

Sharifi

Asadi

Extramedullary plasmacytoma of the sphenoid sinus presenting with visual loss: a case report

Clin Case Rep

2022

;

e05758

. https://doi.org/10.1002/ccr3.5758.

30.

Ampil

Borski

Nathan

CAO

, et al.

Cavernous sinus involvement by extramedullary plasmacytoma of the sphenoid sinus

Leuk Lymphoma

2002

;

2037

–

. https://doi.org/10.1080/1042819021000015998.

31.

Mansouri

Elouaouch

El Youssi

, et al.

Solitary plasmacytoma of the skull base: a case report and literature review

Radiol Case Rep

2023

;

3894

–

. https://doi.org/10.1016/j.radcr.2023.08.027.

32.

Palumbo

Avet-Loiseau

Oliva

, et al.

Revised International Staging System for multiple myeloma: a report from international myeloma working group

J Clin Oncol Off J Am Soc Clin Oncol

2015

;

2863

–

. https://doi.org/10.1200/JCO.2015.61.2267.

Google Scholar

Crossref

WorldCat

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Download all slides

Month:	Total Views:
April 2024	203
May 2024	64
June 2024	57
July 2024	34
August 2024	30
September 2024	26
October 2024	35
November 2024	17
December 2024	8

Article Contents

Sphenoid plasmacytoma as initial presentation of multiple myeloma—case report

Abstract

Introduction

Case report

Discussion

Conclusion

Conflict of interest statement

Funding

References

Citations

Views

Altmetric

Email alerts

Citing articles via

Latest

Most Read

Most Cited

Article Contents

Sphenoid plasmacytoma as initial presentation of multiple myeloma—case report

Abstract

Introduction

Case report

Discussion

Conclusion

Conflict of interest statement

Funding

References

Citations

Views

Altmetric

Email alerts

Citing articles via

Latest

Most Read

Most Cited

This Feature Is Available To Subscribers Only